10.3390/molecules25245763 209 ZaynabM.FatimaM.AbbasS.SharifY.UmairM.ZafarM
The active ingredient (semaglutide) may degrade over time, especially if exposed to temperature fluctuations, light, or moisture
WEGOVYTM is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
CrossRef Htd2 deficiency-associated suppression of -lipoic acid production provokes mitochondrial dysfunction and insulin resistance in adipocytes Mengqi Zeng, Jie Xu, Zhengyi Zhang, Xuan Zou, Xueqiang Wang, Ke Cao, Weiqiang Lv, Yuting Cui, Jiangang Long, Zhihui Feng, Jiankang Liu Redox Biology.2021
There may be moderate side effects, such as mild discomfort at the injection site
Pain 52 LimM